Skip to main content
OpenTrials
Completed

NCT Number: NCT02486614

Effect of Citrate on the Coagulation System in Patients Receiving CRRT

The aim of this study is to evaluate the effect of regional citrate anti-coagulation on different pathways of the coagulation system in critically ill patients with acute kidney injury. This will form the basis for future studies where the investigators plan to focus on patients with premature circuit clotting despite optimal post-filtrate ionised calcium parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Kidney Failure Acute Kidney Injury Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Guy's & St Thomas Hospital

London, SE1 7EH, United Kingdom

About this study

Purpose of clinical trial:

To evaluate the effect of regional citrate anti-coagulation on different pathways of the coagulation system in critically ill patients with acute kidney injury.

Patient population:

critically ill patients with acute kidney injury requiring citrate-based continuous renal replacement therapy (CRRT)

Primary objective:

Changes from baseline in a number of measures of coagulability (platelet count; Prothrombin Time; Activated Partial Thromboplastin Time ratio; fibrinogen; d-dimers; Thrombin generation assay; Clot lysis; platelet function analysis 100) in both the blood within the patient's systemic circulation and the CRRT circuit over the course of 72 hours of regional anticoagulation with citrate.

Number of Subjects/Patients:

12 patients with complete data.

Trial Design:

Prospective non-interventional study.

Endpoints:

Change from baseline in a number of measures of coagulability.

Main Inclusion Criteria:

Adult intensive care patients undergoing CRRT with citrate regional anti-coagulation for AKI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • acute kidney injury treated with citrate based continuous renal replacement therapy (CRRT)
  • age >18 years.
  • expected to require >72 hours of CRRT.

Exclusion criteria

  • Known preexisting clotting tendency
  • Known preexisting bleeding tendency
  • Disseminated Intravascular Coagulation (DIC)
  • Prior transfusion of any blood product in the 24 hours before enrolment
  • Active bleeding (ie. needing blood transfusion) at time of enrolment
  • Haemoglobin at time of enrolment <75g/L
  • Haematocrit at time of enrolment >0.55
  • Patient would refuse Red Blood Cell transfusion (for example Jehova's Witness).
  • Platelet count at time of enrolment <100x103/µL
  • Treatment with any anticoagulant or antiplatelet agent at time of enrolment or within 7 days of enrolment with the exception of heparin or low molecular weight heparin for DVT prophylaxis.
  • Intravenous heparin exposure within 4 hours of commencing citrate anticoagulation.
  • Malnourished: BMI <18.5kg/m2 or unplanned weight loss >10% actual body weight (ABW) in preceding 6 months or BMI <20kg/m2 and unplanned weight loss >5% ABW in preceding 6 months.
  • CRRT prescribed for an indication other than AKI (for example poisoning).

Treatment and study plan

CRRT

Procedure

citrate based continuous renal replacement therapy

Primary outcomes

  1. Changes of parameters of coagulability during Continuous Renal Replacement Therapy (CRRT) with citrate anticoagulation

    Time frame: 72 hours

    Changes of coagulation parameters (Full Blood Count, prothrombin time, activated partial thromboplastin time ratio, fibrinogen, d-dimer, thrombin generation, clot lysis and platelet function analysis) during citrate-based CRRT

Secondary outcomes

  1. Determination of baseline coagulation status before initiation of citrate-based CRRT

    Time frame: Before initiation of CRRT

    Determination of parameters of coagulation [Full Blood Count (FBC), prothrombin time (PT), activated partial thromboplastin time ratio (APTTr), fibrinogen, D-dimers, antithrombin activity, protein C activity, free Protein S antigen, resistance to activated protein C screening, homocysteine, prothrombin 20210 mutation test, factor VIII level, Von Willebrand factor antigen, Dilute Russell's Viper Venom Time, dilute activated partial thromboplastin time, anticardiolipin antibodies, anti-beta 2 glycoprotein I antibodies, thrombin generation assay, clot lysis, platelet function 1+2, Thrombin-Antithrombin and platelet function analysis] before initiation of citrate-based CRRT

Sponsors and collaborators

Lead sponsor

Guy's and St Thomas' NHS Foundation Trust

Other

Registry information

Official study title

The Effect of Regional Citrate Anti-coagulation on the Coagulation System in Critically Ill Patients Receiving Continuous Renal Replacement Therapy for Acute Kidney Injury - an Observational Cohort Study

Acronym: Citroco

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jul 1, 2015
Registry last updated
Oct 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.